Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: Late relapse may occur

被引:20
作者
Boyer, MJ [1 ]
Cox, K [1 ]
Tattersall, MHN [1 ]
Findlay, MPN [1 ]
Grygiel, J [1 ]
Rogers, J [1 ]
机构
[1] ROYAL PRINCE ALFRED HOSP,DEPT UROL,CAMPERDOWN,NSW 2050,AUSTRALIA
关键词
D O I
10.1016/S0090-4295(97)00301-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To review the outcome of men with Stage I nonseminomatous germ cell tumors managed with a policy of active surveillance following orchiectomy. Methods. The clinical records of all men with Stage I nonseminomatous germ cell tumors seen at Royal Prince Alfred Hospital, Australia between 1982 and 1995 were reviewed. Data were obtained concerning the histologic type of tumor, levels of serum tumor markers, relapse and subsequent treatment, and survival. Results. Seventy-seven patients were entered into the active surveillance protocol between 1982 and 1995. With a minimum follow-up of 2 years, 27 (35%) have relapsed, with a median time to relapse of 5 months. Two late relapses occurred at 37 and 57 months after diagnosis. Relapses occurred most commonly in the retroperitoneal lymph nodes, with the lungs the second most common site. Following treatment with chemotherapy and surgery, all patients achieved complete remission, with 1 patient subsequently relapsing and ultimately dying of progressive tumor, One other patient died of acute myeloid leukemia, thought to be secondary to chemotherapy. Overall, 75 patients (97%) remain alive and free of disease. Conclusions. Active surveillance is a safe and effective approach to the management of Stage I nonseminomatous germ cell tumors. Although most relapses occur within the first 2 years, late relapses may occur. (C) 1997, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:588 / 592
页数:5
相关论文
共 21 条
[1]   LACK OF LATE TOXICITY IN PATIENTS TREATED WITH CISPLATIN-CONTAINING COMBINATION CHEMOTHERAPY FOR METASTATIC TESTICULAR CANCER [J].
BOYER, M ;
RAGHAVAN, D ;
HARRIS, PJ ;
LIETCH, J ;
BLEASEL, A ;
WALSH, JC ;
ANDERSON, S ;
TSANG, CS .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :21-26
[2]   RESULTS OF THE SURVEILLANCE POLICY OF STAGE-I NONSEMINOMATOUS GERM-CELL TESTICULAR-TUMORS [J].
COLLS, BM ;
HARVEY, VJ ;
SKELTON, L ;
THOMPSON, PI ;
DADY, PJ ;
FORGESON, GV ;
PEREZ, DJ .
BRITISH JOURNAL OF UROLOGY, 1992, 70 (04) :423-428
[3]  
Damjanov Ivan, 1997, P653
[4]   COMBINATION CHEMOTHERAPY WITH BLEOMYCIN, ETOPOSIDE AND CISPLATIN (BEP) FOR METASTATIC TESTICULAR TERATOMA - LONG-TERM FOLLOW-UP [J].
DEARNALEY, DP ;
HORWICH, A ;
AHERN, R ;
NICHOLLS, J ;
JAY, G ;
HENDRY, WF ;
PECKHAM, MJ .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (06) :684-691
[5]   EVALUATION OF OPTIMAL DURATION OF CHEMOTHERAPY IN FAVORABLE-PROGNOSIS DISSEMINATED GERM-CELL TUMORS - A SOUTHEASTERN-CANCER-STUDY-GROUP PROTOCOL [J].
EINHORN, LH ;
WILLIAMS, SD ;
LOEHRER, PJ ;
BIRCH, R ;
DRASGA, R ;
OMURA, G ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (03) :387-391
[6]  
EINHORN LH, 1981, CANCER RES, V41, P3274
[7]   ORCHIECTOMY ONLY FOR CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TESTIS TUMORS COMPARISON WITH PATHOLOGIC STAGE I DISEASE [J].
FREIHA, F ;
TORTI, F .
UROLOGY, 1989, 34 (06) :347-348
[8]   DETECTION OF RECURRENCE IN PATIENTS WITH CLINICAL STAGE-I NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS AND CONSEQUENCES FOR FURTHER FOLLOW-UP - A SINGLE-CENTER 10-YEAR EXPERIENCE [J].
GELS, ME ;
HOEKSTRA, HJ ;
SLEIJFER, DT ;
MARRINK, J ;
DEBRUIJN, HWA ;
MOLENAAR, WM ;
FRELING, NJM ;
DROSTE, JHJ ;
KOOPS, HS .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1188-1194
[9]  
Kageyama S, 1994, Hinyokika Kiyo, V40, P1021
[10]   A PROSPECTIVE-STUDY OF CISPLATIN-BASED COMBINATION CHEMOTHERAPY IN ADVANCED GERM-CELL MALIGNANCY - ROLE OF MAINTENANCE AND LONG-TERM FOLLOW-UP [J].
LEVI, JA ;
THOMSON, D ;
SANDEMAN, T ;
TATTERSALL, M ;
RAGHAVAN, D ;
BYRNE, M ;
GILL, G ;
HARVEY, V ;
BURNS, I ;
SNYDER, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1154-1160